Arthur Krieg to Female
This is a "connection" page, showing publications Arthur Krieg has written about Female.
Connection Strength
0.426
-
Subramanian RR, Wysk MA, Ogilvie KM, Bhat A, Kuang B, Rockel TD, Weber M, Uhlmann E, Krieg AM. Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers. Nucleic Acids Res. 2015 Oct 30; 43(19):9123-32.
Score: 0.028
-
Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A, Akira S, Kelly KM, Reeves WH, Bauer S, Krieg AM. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med. 2005 Dec 05; 202(11):1575-85.
Score: 0.014
-
Butler JE, Francis DH, Freeling J, Weber P, Krieg AM. Antibody repertoire development in fetal and neonatal piglets. IX. Three pathogen-associated molecular patterns act synergistically to allow germfree piglets to respond to type 2 thymus-independent and thymus-dependent antigens. J Immunol. 2005 Nov 15; 175(10):6772-85.
Score: 0.014
-
Davar D, Morrison RM, Dzutsev AK, Karunamurthy A, Chauvin JM, Amatore F, Deutsch JS, Das Neves RX, Rodrigues RR, McCulloch JA, Wang H, Hartman DJ, Badger JH, Fernandes MR, Bai Y, Sun J, Cole AM, Aggarwal P, Fang JR, Deitrick C, Bao R, Duvvuri U, Sridharan SS, Kim SW, A Choudry H, Holtzman MP, Pingpank JF, O'Toole JP, DeBlasio R, Jin Y, Ding Q, Gao W, Groetsch C, Pagliano O, Rose A, Urban C, Singh J, Divarkar P, Mauro D, Bobilev D, Wooldridge J, Krieg AM, Fury MG, Whiteaker JR, Zhao L, Paulovich AG, Najjar YG, Luke JJ, Kirkwood JM, Taube JM, Park HJ, Trinchieri G, Zarour HM. Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell. 2024 Nov 11; 42(11):1898-1918.e12.
Score: 0.013
-
Vollmer J, Weeratna RD, Jurk M, Samulowitz U, McCluskie MJ, Payette P, Davis HL, Schetter C, Krieg AM. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology. 2004 Oct; 113(2):212-23.
Score: 0.013
-
Vollmer J, Weeratna RD, Jurk M, Davis HL, Schetter C, W?llner M, Wader T, Liu M, Kritzler A, Krieg AM. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. J Leukoc Biol. 2004 Sep; 76(3):585-93.
Score: 0.013
-
Margalit O, Lieberman S, Redinsky I, Halparin S, Honig N, Raskin S, Ben-Ayun M, Shacham-Shmueli E, Halpern N, Urban D, Ackerstein A, Shulman K, Ben-Ami E, Semenisty V, Purim O, Yarom N, Golan T, Boursi B, Appel S, Symon Z, Berger R, Mauro D, Krieg AM, Lawrence YR. Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases. Clin Colorectal Cancer. 2023 12; 22(4):442-449.e1.
Score: 0.012
-
Ray NB, Krieg AM. Oral pretreatment of mice with CpG DNA reduces susceptibility to oral or intraperitoneal challenge with virulent Listeria monocytogenes. Infect Immun. 2003 Aug; 71(8):4398-404.
Score: 0.012
-
Sandler AD, Chihara H, Kobayashi G, Zhu X, Miller MA, Scott DL, Krieg AM. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res. 2003 Jan 15; 63(2):394-9.
Score: 0.012
-
Hunter SK, Andracki ME, Krieg AM. Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice. Am J Obstet Gynecol. 2001 Nov; 185(5):1174-9.
Score: 0.011
-
Chen Y, Lenert P, Weeratna R, McCluskie M, Wu T, Davis HL, Krieg AM. Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs. Gene Ther. 2001 Jul; 8(13):1024-32.
Score: 0.010
-
Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000 Feb 01; 164(3):1617-24.
Score: 0.010
-
Lemke-Miltner CD, Blackwell SE, Yin C, Krug AE, Morris AJ, Krieg AM, Weiner GJ. Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization. J Immunol. 2020 03 01; 204(5):1386-1394.
Score: 0.009
-
Older SA, Battafarano DF, Enzenauer RJ, Krieg AM. Can immunization precipitate connective tissue disease? Report of five cases of systemic lupus erythematosus and review of the literature. Semin Arthritis Rheum. 1999 Dec; 29(3):131-9.
Score: 0.009
-
Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, Yi AK, Short D, Davis HL. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A. 1998 Oct 13; 95(21):12631-6.
Score: 0.009
-
Krieg AM, Love-Homan L, Yi AK, Harty JT. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol. 1998 Sep 01; 161(5):2428-34.
Score: 0.009
-
Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine. 1998 Jul; 16(11-12):1216-24.
Score: 0.009
-
Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997 Sep 30; 94(20):10833-7.
Score: 0.008
-
Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 1996 Apr 02; 93(7):2879-83.
Score: 0.007
-
Cupisti K, Lehwald N, Anlauf M, Riemer J, Werner TA, Krieg A, Witte J, Chanab A, Baldus SE, Krausch M, Raffel A, Herdter C, Schott M, Knoefel WT. Encapsulation status of papillary thyroid microcarcinomas is associated with the risk of lymph node metastases and tumor multifocality. Horm Metab Res. 2014 Feb; 46(2):138-44.
Score: 0.006
-
Rees DG, Phillpotts RJ, Griffin KF, Lukaszewski RA, Laws TR, Atkins HS, Krieg AM, Titball RW. CpG oligonucleotides protect against Venezuelan equine encephalitis virus infection in a route-dependent manner. Int J Antimicrob Agents. 2013 Dec; 42(6):587-8.
Score: 0.006
-
La Rosa C, Longmate J, Lacey SF, Kaltcheva T, Sharan R, Marsano D, Kwon P, Drake J, Williams B, Denison S, Broyer S, Couture L, Nakamura R, Dadwal S, Kelsey MI, Krieg AM, Diamond DJ, Zaia JA. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis. 2012 Apr 15; 205(8):1294-304.
Score: 0.006
-
Knoefel WT, Alexander A, Tustas RY, Schmelzle M, Klein HM, Krieg A, Topp SA, Eisenberger CF, Fuerst G, Schulte am Esch J. [Stem cell-induced liver regeneration]. Zentralbl Chir. 2013 Apr; 138(2):166-72.
Score: 0.005
-
Easton A, Haque A, Chu K, Patel N, Lukaszewski RA, Krieg AM, Titball RW, Bancroft GJ. Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. J Infect Dis. 2011 Aug 15; 204(4):636-44.
Score: 0.005
-
Nichani AK, Dar MA, Mirakhur KK, Krieg AM, Booth JS, Townsend HG, Potter AA, Babiuk LA, Mutwiri GK. Subcutaneous, but not intratracheal administration of the TLR9 agonist, CpG DNA transiently reduces parainfluenza-3 virus shedding in newborn lambs. Comp Immunol Microbiol Infect Dis. 2010 Dec; 33(6):e111-7.
Score: 0.005
-
Tluk S, Jurk M, Forsbach A, Weeratna R, Samulowitz U, Krieg AM, Bauer S, Vollmer J. Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses. Int Immunol. 2009 May; 21(5):607-19.
Score: 0.004
-
Amemiya K, Meyers JL, Rogers TE, Fast RL, Bassett AD, Worsham PL, Powell BS, Norris SL, Krieg AM, Adamovicz JJ. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague. Vaccine. 2009 Apr 06; 27(16):2220-9.
Score: 0.004
-
Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother. 2008 Oct; 31(8):781-91.
Score: 0.004
-
Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G, Al-Adhami M, Readett D, Krieg AM, Leichman CG. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Aug 20; 26(24):3979-86.
Score: 0.004
-
Fukuiwa T, Sekine S, Kobayashi R, Suzuki H, Kataoka K, Gilbert RS, Kurono Y, Boyaka PN, Krieg AM, McGhee JR, Fujihashi K. A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine. 2008 Sep 02; 26(37):4849-59.
Score: 0.004
-
Bhan U, Trujillo G, Lyn-Kew K, Newstead MW, Zeng X, Hogaboam CM, Krieg AM, Standiford TJ. Toll-like receptor 9 regulates the lung macrophage phenotype and host immunity in murine pneumonia caused by Legionella pneumophila. Infect Immun. 2008 Jul; 76(7):2895-904.
Score: 0.004
-
Forsbach A, Nemorin JG, Montino C, M?ller C, Samulowitz U, Vicari AP, Jurk M, Mutwiri GK, Krieg AM, Lipford GB, Vollmer J. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol. 2008 Mar 15; 180(6):3729-38.
Score: 0.004
-
Martinson JA, Roman-Gonzalez A, Tenorio AR, Montoya CJ, Gichinga CN, Rugeles MT, Tomai M, Krieg AM, Ghanekar S, Baum LL, Landay AL. Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. Cell Immunol. 2007 Nov-Dec; 250(1-2):75-84.
Score: 0.004
-
Matthaei H, Boelke E, Eisenberger CF, Alldinger I, Krieg A, Schmelzle M, Poremba C, Schellhammer F, Knoefel WT, Budach W, Peiper M. Interdisciplinary treatment of primary hepatic angiosarcoma: emergency tumor embolization followed by elective surgery. Eur J Med Res. 2007 Dec 14; 12(12):591-4.
Score: 0.004
-
Stewart VA, McGrath S, Krieg AM, Larson NS, Angov E, Smith CL, Brewer TG, Heppner DG. Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques. Clin Vaccine Immunol. 2008 Feb; 15(2):221-6.
Score: 0.004
-
Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, Hainsworth J, Sparano JA, Tsai DE, Horning S, Krieg AM, Weiner GJ. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res. 2007 Oct 15; 13(20):6168-74.
Score: 0.004
-
Bhan U, Lukacs NW, Osterholzer JJ, Newstead MW, Zeng X, Moore TA, McMillan TR, Krieg AM, Akira S, Standiford TJ. TLR9 is required for protective innate immunity in Gram-negative bacterial pneumonia: role of dendritic cells. J Immunol. 2007 Sep 15; 179(6):3937-46.
Score: 0.004
-
Martinson JA, Tenorio AR, Montoya CJ, Al-Harthi L, Gichinga CN, Krieg AM, Baum LL, Landay AL. Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology. 2007 Apr; 120(4):526-35.
Score: 0.004
-
Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Laframboise C, Leese P, Krieg AM, Efler SM, Davis HL. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther. 2007; 12(5):741-51.
Score: 0.004
-
Pashenkov M, Go?ss G, Wagner C, H?rmann M, Jandl T, Moser A, Britten CM, Smolle J, Koller S, Mauch C, Tantcheva-Poor I, Grabbe S, Loquai C, Esser S, Franckson T, Schneeberger A, Haarmann C, Krieg AM, Stingl G, Wagner SN. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol. 2006 Dec 20; 24(36):5716-24.
Score: 0.004
-
Weigel BJ, Panoskaltsis-Mortari A, Diers M, Garcia M, Lees C, Krieg AM, Chen W, Blazar BR. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. Exp Hematol. 2006 Oct; 34(10):1403-12.
Score: 0.004
-
Booth JS, Nichani AK, Benjamin P, Dar A, Krieg AM, Babiuk LA, Mutwiri GK. Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells. Vet Immunol Immunopathol. 2007 Jan 15; 115(1-2):24-34.
Score: 0.004
-
Link BK, Ballas ZK, Weisdorf D, Wooldridge JE, Bossler AD, Shannon M, Rasmussen WL, Krieg AM, Weiner GJ. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother. 2006 Sep-Oct; 29(5):558-68.
Score: 0.004
-
Ohashi K, Kobayashi G, Fang S, Zhu X, Antonia SJ, Krieg AM, Sandler AD. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. J Pediatr Surg. 2006 Aug; 41(8):1361-8.
Score: 0.004
-
Wang Y, Abel K, Lantz K, Krieg AM, McChesney MB, Miller CJ. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J Virol. 2005 Nov; 79(22):14355-70.
Score: 0.004
-
Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, Krieg AM, Cameron DW. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS. 2005 Sep 23; 19(14):1473-9.
Score: 0.004
-
Saha A, Baral RN, Chatterjee SK, Mohanty K, Pal S, Foon KA, Primus FJ, Krieg AM, Weiner GJ, Bhattacharya-Chatterjee M. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. Cancer Immunol Immunother. 2006 May; 55(5):515-27.
Score: 0.003
-
Noll BO, McCluskie MJ, Sniatala T, Lohner A, Yuill S, Krieg AM, Schetter C, Davis HL, Uhlmann E. Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration. Biochem Pharmacol. 2005 Mar 15; 69(6):981-91.
Score: 0.003
-
Rees DG, Gates AJ, Green M, Eastaugh L, Lukaszewski RA, Griffin KF, Krieg AM, Titball RW. CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Antiviral Res. 2005 Feb; 65(2):87-95.
Score: 0.003
-
Edwards L, Williams AE, Krieg AM, Rae AJ, Snelgrove RJ, Hussell T. Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner. Eur J Immunol. 2005 Jan; 35(1):273-81.
Score: 0.003
-
Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004 Nov; 24(6):693-701.
Score: 0.003
-
Deng JC, Moore TA, Newstead MW, Zeng X, Krieg AM, Standiford TJ. CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. J Immunol. 2004 Oct 15; 173(8):5148-55.
Score: 0.003
-
Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y, Laframboise C, Al Adhami MJ, Khaliq Y, Seguin I, Cameron DW. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine. 2004 Aug 13; 22(23-24):3136-43.
Score: 0.003
-
Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res. 2003 Aug 01; 9(8):3105-14.
Score: 0.003
-
Hirunpetcharat C, Wipasa J, Sakkhachornphop S, Nitkumhan T, Zheng YZ, Pichyangkul S, Krieg AM, Walsh DS, Heppner DG, Good MF. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides. Vaccine. 2003 Jun 20; 21(21-22):2923-32.
Score: 0.003
-
Lenert P, Yi AK, Krieg AM, Stunz LL, Ashman RF. Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells. Antisense Nucleic Acid Drug Dev. 2003; 13(3):143-50.
Score: 0.003
-
Weigel BJ, Nath N, Taylor PA, Panoskaltsis-Mortari A, Chen W, Krieg AM, Brasel K, Blazar BR. Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. Blood. 2002 Dec 01; 100(12):4169-76.
Score: 0.003
-
Gierynska M, Kumaraguru U, Eo SK, Lee S, Krieg A, Rouse BT. Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes. J Virol. 2002 Jul; 76(13):6568-76.
Score: 0.003
-
Stunz LL, Lenert P, Peckham D, Yi AK, Haxhinasto S, Chang M, Krieg AM, Ashman RF. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol. 2002 05; 32(5):1212-22.
Score: 0.003
-
Pontarollo RA, Rankin R, Babiuk LA, Godson DL, Griebel PJ, Hecker R, Krieg AM, van Drunen Littel-van den Hurk S. Monocytes are required for optimum in vitro stimulation of bovine peripheral blood mononuclear cells by non-methylated CpG motifs. Vet Immunol Immunopathol. 2002 Jan 01; 84(1-2):43-59.
Score: 0.003
-
Rankin R, Pontarollo R, Ioannou X, Krieg AM, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001 Oct; 11(5):333-40.
Score: 0.003
-
Chen Y, Zhang J, Moore SA, Ballas ZK, Portanova JP, Krieg AM, Berg DJ. CpG DNA induces cyclooxygenase-2 expression and prostaglandin production. Int Immunol. 2001 Aug; 13(8):1013-20.
Score: 0.003
-
Myers LP, Krieg AM, Pruett SB. Bacterial DNA does not increase serum corticosterone concentration or prevent increases induced by other stimuli. Int Immunopharmacol. 2001 Aug; 1(8):1605-14.
Score: 0.003
-
Lenert P, Stunz L, YI AK, Krieg AM, Ashman RF. CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. Antisense Nucleic Acid Drug Dev. 2001 Aug; 11(4):247-56.
Score: 0.003
-
Warren TL, Bhatia SK, Acosta AM, Dahle CE, Ratliff TL, Krieg AM, Weiner GJ. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol. 2000 Dec 01; 165(11):6244-51.
Score: 0.003
-
Brunner C, Seiderer J, Schlamp A, Bidlingmaier M, Eigler A, Haimerl W, Lehr HA, Krieg AM, Hartmann G, Endres S. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol. 2000 Dec 01; 165(11):6278-86.
Score: 0.003
-
McCluskie MJ, Weeratna RD, Krieg AM, Davis HL. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine. 2000 Nov 22; 19(7-8):950-7.
Score: 0.003
-
Kline JN, Krieg AM, Waldschmidt TJ, Ballas ZK, Jain V, Businga TR. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J Allergy Clin Immunol. 1999 Dec; 104(6):1258-64.
Score: 0.002
-
Jones TR, Obaldia N, Gramzinski RA, Charoenvit Y, Kolodny N, Kitov S, Davis HL, Krieg AM, Hoffman SL. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine. 1999 Aug 06; 17(23-24):3065-71.
Score: 0.002
-
Chu RS, Askew D, Noss EH, Tobian A, Krieg AM, Harding CV. CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing. J Immunol. 1999 Aug 01; 163(3):1188-94.
Score: 0.002
-
Walker PS, Scharton-Kersten T, Krieg AM, Love-Homan L, Rowton ED, Udey MC, Vogel JC. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci U S A. 1999 Jun 08; 96(12):6970-5.
Score: 0.002
-
Liu HM, Newbrough SE, Bhatia SK, Dahle CE, Krieg AM, Weiner GJ. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood. 1998 Nov 15; 92(10):3730-6.
Score: 0.002
-
Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol. 1998 Sep 15; 161(6):3042-9.
Score: 0.002
-
Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM, Weeranta R. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol. 1998 Jan 15; 160(2):870-6.
Score: 0.002
-
Chace JH, Hooker NA, Mildenstein KL, Krieg AM, Cowdery JS. Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol. 1997 Aug; 84(2):185-93.
Score: 0.002
-
Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 1997 Apr 15; 89(8):2994-8.
Score: 0.002
-
Ishigatsubo Y, Steinberg AD, Krieg A, Klinman DM. Increased utilization of polyreactive B cells during periods of generalized immune activation. Autoimmunity. 1995; 22(2):113-9.
Score: 0.002
-
Steinberg AD, Krieg AM, Takashi T, Gourley MF. Timing of immunosuppression in the natural history of autoimmune diseases. J Autoimmun. 1992 Apr; 5 Suppl A:197-203.
Score: 0.001
-
Klinman DM, Krieg A, Conover J, Ussery MA, Black PL. Effect of cyclophosphamide, total body irradiation, and zidovudine on retrovirus proliferation and disease progression in murine AIDS. AIDS Res Hum Retroviruses. 1992 Jan; 8(1):101-6.
Score: 0.001